NASDAQ · NGNE
Healthcare · Biotechnology
$25.65
Down-$0.90 (-3.39%)
Updated Oct 3, 2026, 10:00 AM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · NGNE
1M range · 0 trading sessions · Daily adjusted prices
NGNE does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning NGNE.
Company
Market Activity
Research & News
NGNE research
Company profile and research snapshot.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 12, 2026 | Canaccord Genuity | Buy | — |
| Aug 12, 2026 | Guggenheim | Buy | — |
| Aug 12, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 9, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 6, 2026 | Canaccord Genuity | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 8, 2026
NEW YORK, September 08, 2026--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the H.C. Wainwright 28th Annual Global Investment Conference.
Benzinga · Aug 12, 2026
Canaccord Genuity analyst Whitney Ijem maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers the price target from $180 to $166.
Benzinga · Aug 12, 2026
Guggenheim analyst Debjit Chattopadhyay maintains Neurogene (NASDAQ:NGNE) with a Buy and raises the price target from $69 to $81.
Benzinga · Aug 12, 2026
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers the price target from $70 to $65.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NGNE.
